Given that there are no major, obvious differences in tolerability, efficacy on glycemic parameters, weight loss, or overt advantages regarding administration, it is likely that the use of LIXI in place of other GLP-1 agonists will be based on cost (79)
This structural modification enhances lixisenatides resistance to physiological degradation by DPP-IV, resulting in a half-life of approximately 24 h
[00:18:26] Emily Field: Research suggests that without intervention, adults roughly lose about three to 8% of their muscle mass per decade, and that rate of weight loss tends to accelerate after age 60, especially if someone is sedentary or not engaging in resistance training
GLP-1 receptor agonists work by mimicking incretin hormones that regulate insulin secretion, appetite signalling, and gastric function as described in clinical pharmacology literature [1]